These immunizing peptide antigens were co-administered with an amphiphile-adjuvant CpG-7909 in 25 patients with surgically resected stage I-IV PDAC (n = 20) and CRC (n = 5) who had no evidence of disease on imaging but had detectable MRD+ (ctDNA positive in n = 13/25, CA19-9 and/or carcinoembryonic antigen (CEA) criteria in n = 7/25, or both n = 5/25; Extended Data Fig. 1 and Extended Data Table 1). The gene discussed is CEACAM5; the disease is colorectal carcinoma.